Printer Friendly

DEPRENYL ANIMAL HEALTH GRANTED PATENT FOR L-DEPRENYL (ANIPRYL) AS TREATMENT OF COGNITIVE DYSFUNCTION IN DOGS

 DEPRENYL ANIMAL HEALTH GRANTED PATENT FOR L-DEPRENYL
 (ANIPRYL) AS TREATMENT OF COGNITIVE DYSFUNCTION IN DOGS
 OVERLAND PARK, Kan., July 6 /PRNewswire/ -- Deprenyl Animal Health, Inc. (NASDAQ: DAHI, TSE: DAH) reported today that the United States Patent & Trademark Office has granted the company a patent for the treatment of cognitive dysfunction in dogs with l-deprenyl (Anipryl(R)).
 This patent gives Deprenyl Animal Health 17 years of commercial exclusivity on the use of l-deprenyl (Anipryl) in dogs for the treatment of various cognitive disorders including memory loss and associated afflictions of mid and old age.
 The company also reported that it is proceeding to satisfy the premarket approval requirements for Anipryl before the U.S. Food and Drug Administration (FDA) and Canada's Bureau of Veterinary Medicine (BVM).
 Deprenyl Animal Health said that it has several additional pending patent claims pertaining to the use of l-deprenyl (Anipryl) for treating various medical conditions in companion dogs.
 In announcing the company's first patent, David R. Stevens, president, said, "As in other species, including humans, many dogs experience loss of cognitive abilities with advancing age. This problem varies from mild to serious, and may lead to the euthanasia of the pet, particularly when the animal fails to recognize its owners, remember common commands, or otherwise becomes "non-functional." The diagnosis and therapy of cognitive dysfunction is relatively new in veterinary medicine, and Anipryl therapy may be a significant advance in the practice of veterinary medicine, to the benefit of both companion animals and their owners.
 "We are extremely pleased with this development," Stevens added, "inasmuch as we have invested substantial resources over a two year period to develop our invention. We intend to pursue the additional pending claims as we continue to establish the substantial utility of this pharmaceutical in veterinary medicine."
 The company previously announced the filing of a U.S. patent application for treating dogs afflicted with Cushing's disease with l-deprenyl, and has announced an exclusive license agreement with the Innovations Foundation, University of Toronto, for its patent applications that disclose the treatment of nervous tissue damage with l-deprenyl.
 Deprenyl Animal Health was established to develop for the United States and Canadian markets animal health applications for the pharmaceutical l-deprenyl (Anipryl). The company is seeking regulatory approval in the United States and Canada for veterinary prescriptive applications of Anipryl (l-deprenyl), in dogs. The company is also identifying other animal health product opportunities to become a multi- product animal health pharmaceutical company. In pursuit of this objective, DAHI announced on June 24 that it had purchased a 12.5 percent equity position in Phoenix Scientific, Inc. a pharmaceutical manufacturing company specializing in the production of generic animal pharmaceuticals.
 Deprenyl Research Limited, Toronto, (NASDAQ: DEPLF, TSE: DEP) owns approximately 40 percent of the common stock of DAHI.
 -0- 7/6/92
 /CONTACT: David R. Stevens, president of Deprenyl Animal Health, 913-338-2120, or Irving L. Straus of Straus Corporate Communications, 212-768-2477, for Deprenyl Animal Health/
 (DAHI DEPLF) CO: Deprenyl Animal Health, Inc. ST: Kansas IN: MTC SU:


SH-OS -- NY040 -- 6672 07/06/92 14:09 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1992
Words:508
Previous Article:KMART CELEBRATES GRAND OPENING OF SOUTHBURY, CONN., STORE
Next Article:FLORIDA DEPARTMENT OF BANKING AND FINANCE AND FEDERAL RESERVE BANK OF ATLANTA AGREE ON EXAMINATIONS OF STATE-CHARTERED FEDERAL RESERVE BANKS
Topics:


Related Articles
DEPRENYL ANIMAL HEALTH REPORTS PRELIMINARY POSITIVE RESULTS IN USE OF ANIPRYL (L-DEPRENYL) FOR CUSHING'S DISEASE IN DOGS
DEPRENYL ANIMAL HEALTH REPORTS RESULTS OF OPERATIONS FOR THREE AND SIX MONTHS ENDED JUNE 30, 1992
DEPRENYL ANIMAL HEALTH, INC. REPORTS U.S. PATENT ALLOWANCE FOR USE OF ANIPRYL IN TREATMENT OF CANINE CUSHING'S DISEASE
DEPRENYL ANIMAL HEALTH, INC. REPORTS RESULTS OF OPERATIONS FOR THREE MONTHS ENDED SEPT. 30, 1992
DEPRENYL ANIMAL HEALTH, INC. REPORTS PRELIMINARY POSITIVE RESULTS IN USE OF ANIPRYL FOR TREATING COGNITIVE DYSFUNCTION (DEMENTIA) IN PET DOGS
DEPRENYL ANIMAL HEALTH INC. SECURES ADDITIONAL FUNDING FROM DEPRENYL RESEARCH; DRL COMMITS $2.5 MILLION TO FUND DAHI OPERATIONS THROUGH 1995
DEPRENYL ANIMAL HEALTH AND HOECHST VETERINAE ENTER INTO LICENSE AND SUPPLY AGREEMENT FOR EUROPEAN DEVELOPMENT AND MARKETING OF ANIPRYL
DEPRENYL ANIMAL HEALTH INC. REPORTS RESULTS OF OPERATIONS FOR THREE AND SIX MONTHS ENDED JUNE 30, 1994
DEPRENYL ANIMAL HEALTH INC. ACHIEVES FIRST EUROPEAN PATENT AND FIFTH U.S. PATENT FOR ANIPRYL(R) THERAPY
DEPRENYL ANIMAL HEALTH INC. REPORTS RESULTS OF OPERATIONS FOR THREE MONTHS ENDED MARCH 31, 1995

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters